Technopath Clinical Diagnostics Launches the First Not-For-Profit COVID-19 Antibody Testing Initiative to Support Companies in Ireland
PR84224
BALLINA (County Tipperary), Ireland, June 2, 2020 /PRNewswire=KYODO JBN/ --
Technopath Clinical Diagnostics today announced that it is rolling out COVID-19
antibody testing in Ireland to help businesses navigate a safer workplace
re-entry. This initiative will provide key services to all industries and will
be offered on a not-for-profit basis. As a global leader in the development of
quality control materials for the Diagnostics Industry, Technopath has been
hands-on since the beginning of the COVID-19 pandemic supporting many of the
larger global diagnostic companies as they develop antibody tests.
From recently launching the world's first third-party COVID-19 quality control
solutions allowing clinical laboratories to release patient test results with
confidence, Technopath is now offering its expertise, equipment and facilities
to provide antibody testing for businesses in Ireland using both the Abbott
Diagnostics and Roche Diagnostics testing platforms. The company believes
COVID-19 antibody testing could be part of the solution to reopening the
nation's economy.
"Companies in Ireland as well as around the world are looking for ways to
reopen their businesses by taking every step to reduce the risk of coronavirus
exposure while making employees feel safe returning to work," said Malcolm
Bell, CEO and founder of Technopath. "Given that the Department of Health is
now indicating that our nation may be facing a prolonged acute emergency for
the foreseeable future, there is an urgent need to equip companies with the
opportunity to offer their employees antibody tests. Underscored by our deep
experience in supporting diagnostic companies, these tests are assuming greater
importance in helping companies get back to work."
For the initial phase of the COVID-19 antibody testing initiative, Technopath
is partnering with Corporate Health Ireland, facilitating the immediate and
professional collection of blood samples ensuring secure and client
confidential reporting of results by one of the country's leading providers of
occupational health services.
Phase Two will explore partnering with other occupational health providers in
Ireland to make antibody tests available at workplaces helping to control the
spread of future COVID-19 infections. Furthermore, these tests will enable
people who have the antibodies in their blood an opportunity to donate their
plasma for therapeutic use and potentially help people with the most severe
cases of COVID-19 to recover more quickly.
For more about Technopath please visit:
https://www.technopathclinicaldiagnostics.com/about/our-company/
Logo - https://mma.prnewswire.com/media/1165846/Technopath_Logo.jpg
For Media:
Sunny Uberoi, Corporate Communications, + 1 917 747 2018, sunny@166media.com
For Corporate Health Ireland: Dr. Martin Hogan MB FRCPI FFOM, Director,
Corporate Health Ireland Ltd., +353 (0)21 435 0360, martin.hogan@CHI.ie
For Marketing & Communications: Len Lloyd, Director Marketing, Technopath
Clinical Diagnostics, + 353 61 525700, len.lloyd@technopathcd.com
Source: Technopath Clinical Diagnostics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。